Entering text into the input field will update the search result below

Pfizer's Herceptin biosimilar candidate successful in late-stage study

Nov. 30, 2016 8:54 AM ETPfizer Inc. (PFE) StockBy: Douglas W. House, SA News Editor
  • A Phase 3 clinical trial, REFLECTIONS B3271002, comparing the safety and efficacy of Pfizer's (NYSE:PFE) biosimilar PF-05280014 to Roche's (OTCQX:RHHBY) Herceptin (trastuzumab) met the primary endpoint of showing equivalence as measured by objective response rate (ORR), taken in combination with paclitaxel, in first-line patients with HER-positive metastatic breast cancer.
  • A separate study, REFLECTIONS B3271004, in early breast cancer patients was also successful.
  • The development of PF-05280014 is ongoing. According to ClinicalTrials.gov, there are four studies currently recruiting patients and five that are active with recruiting completed.

Recommended For You

More Trending News

About PFE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PFE--
Pfizer Inc.